| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Hybritech, Inc., San Diego, California 92121 [S. D. M., K. M. M., L. S. M., A. K., M. S. S., J. K. P., C. L. E., C. L. G., H. J. L., H. G. R.], and University of California, Irvine Medical Center, Department of Pathology, Orange, California 92868 [P. C.]
Prostate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa) but has limited specificity for distinguishing early PCa from benign prostatic hyperplasia, because both PCa and benign prostatic hyperplasia release PSA into the serum. We have identified previously a truncated form of precursor PSA (pPSA) in prostate tumor extracts consisting of PSA with a serine-arginine pro leader peptide ([-2]pPSA) instead of the normally expressed 7 amino acid pro leader peptide. In the current study we developed monoclonal antibodies to detect [-2]pPSA and other isoforms of pPSA for Western blot analysis. PSA was immunoaffinity purified from 100 to 200 ml of serum from each of five men with biopsy-proven cancer and three biopsy-negative men, all with total PSA levels in the diagnostically relevant range near 10 ng/ml. The truncated [-2]pPSA was estimated to range from 25 to 95% of the free PSA in the five PCa samples but only 6–19% of the free PSA in the biopsy-negative men. Immunohistochemical studies showed positive staining for [-2]pPSA in PCa epithelium and that [-2]pPSA was enriched in cancer cell secretions. In vitro activation studies showed that human kallikrein 2 and trypsin readily activated full-length pPSA but were unable to activate [-2]pPSA to mature PSA. Thus, [-2]pPSA, once formed, is a stable but inactive isoform of PSA. Truncated [-2]pPSA may represent an important new diagnostic marker for the early detection of PCa.
This article has been cited by other articles:
|
|
 |
|
  D. Nedelkov, U. A. Kiernan, E. E. Niederkofler, K. A. Tubbs, and R. W. Nelson Population Proteomics: The Concept, Attributes, and Potential for Cancer Biomarker Research Mol. Cell. Proteomics, October 1, 2006; 5(10): 1811 - 1818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jung, J. Reiche, A. Boehme, C. Stephan, S. A. Loening, D. Schnorr, W. Hoesel, and P. Sinha Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer Clin. Chem., December 1, 2004; 50(12): 2292 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Mikolajczyk, W. J. Catalona, C. L. Evans, H. J. Linton, L. S. Millar, K. M. Marker, D. Katir, A. Amirkhan, and H. G. Rittenhouse Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate Cancer Clin. Chem., June 1, 2004; 50(6): 1017 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wu, L. Zhu, U.-H. Stenman, and J. Leinonen Immunopeptidometric Assay for Enzymatically Active Prostate-Specific Antigen Clin. Chem., January 1, 2004; 50(1): 125 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Haese, V. Vaisanen, J. A. Finlay, K. Pettersson, H. G. Rittenhouse, A. W. Partin, D. J. Bruzek, L. J. Sokoll, H. Lilja, and D. W. Chan Standardization of Two Immunoassays for Human Glandular Kallikrein 2 Clin. Chem., April 1, 2003; 49(4): 601 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Blijenberg, M. F. Wildhagen, C. H. Bangma, J. A. Finlay, V. Vaisanen, and F. H. Schroder Comparison of Two Assays for Human Kallikrein 2 Clin. Chem., February 1, 2003; 49(2): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Linton, L. S. Marks, L. S. Millar, C. L. Knott, H. G. Rittenhouse, and S. D. Mikolajczyk Benign Prostate-specific Antigen (BPSA) in Serum Is Increased in Benign Prostate Disease Clin. Chem., February 1, 2003; 49(2): 253 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Balk, Y.-J. Ko, and G. J. Bubley Biology of Prostate-Specific Antigen J. Clin. Oncol., January 15, 2003; 21(2): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Isono, T. Tanaka, S. Kageyama, and T. Yoshiki Structural Diversity of Cancer-related and Non-Cancer-related Prostate-specific Antigen Clin. Chem., December 1, 2002; 48(12): 2187 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Leinonen, P. Wu, and U.-H. Stenman Epitope Mapping of Antibodies against Prostate-specific Antigen with Use of Peptide Libraries Clin. Chem., December 1, 2002; 48(12): 2208 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Niemela, J. Lovgren, M. Karp, H. Lilja, and K. Pettersson Sensitive and Specific Enzymatic Assay for the Determination of Precursor Forms of Prostate-specific Antigen after an Activation Step Clin. Chem., August 1, 2002; 48(8): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stephan, H. Cammann, A. Semjonow, E. P. Diamandis, L. F.A. Wymenga, M. Lein, P. Sinha, S. A. Loening, and K. Jung Multicenter Evaluation of an Artificial Neural Network to Increase the Prostate Cancer Detection Rate and Reduce Unnecessary Biopsies Clin. Chem., August 1, 2002; 48(8): 1279 - 1287. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
